

Product Name: WZ4002 Revision Date: 01/10/2021

Product Data Sheet

WZ4002

Cat. No.: A1389

CAS No.: 1213269-23-8
Formula: C25H27CIN6O3


M.Wt: 494.18

Synonyms:

Target: JAK/STAT Signaling

Pathway: EGFR

Storage: Store at -20°C



Solvent & Solubility

≥24.7 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH

In Vitro

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.0236 mL	10.1178 mL	20.2355 mL
	5 mM	0.4047 mL	2.0236 mL	4.0471 mL
	10 mM	0.2024 mL	1.0118 mL	2.0236 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent
IC ₅₀ & Target	2 nM (EGFRL858R), 8 nM (EGFRL858R/T790M)

Cell Viability Assay

Con Tlability Accay	
Cell Line:	EGFR-mutated NSCLC cell lines PC-9 and NCI-H1975 (H1975)
Preparation method:	The solubility of this compound in DMSO is >24.7mg/mL. General tips for
	obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes
	and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
	below -20°C for several months.
Reacting conditions:	1-40 nM (PC-9G cells) and 0-1000 nM (H1975 cells); 72 h
	A Lucian and the area

	Applications:	In PC-9G and H1975 cells, WZ4002 alone reduced the cell viability in a small		
		amount, and combining WZ4002 with SAHA significantly decreased cell		
		viability for both cell lines. Combined treatment of WZ4002 with SAHA		
		significantly enhanced bcl-xL decrement, caspase 3 activation and PARP		
		cleavage. In PC-9G cells, combining WZ4002 with SAHA also enhanced		
	210	autophagy.		
	Animal experiment			
	Animal models:	nude mice xenografted with H1975 cells		
	Dosage form:	25 mg/kg; oral gavage for 5 days per week; 3 weeks		
	Applications:	In nude mice xenografted with H1975 cells, WZ4002 resulted in only a marginal		
		decrease in tumor volume, whereas treatment with the combination of WZ4002		
In Vivo		and SAHA led to a marked shrinkage of tumor. In H1975 tumors, Combined		
		treatment of WZ4002 with SAHA decreased expression of bcl-2 and bcl-xL and		
		increased PARP cleavage, which then enhanced apoptosis and autophagy.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may		
	DE LOCALITA	slightly differ with the theoretical value. This is caused by an experimental		
	Action of the Control	system error and it is normal.		

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Lee TG1, Jeong EH, Kim SY, et al. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer. Int J Cancer. 2015 Jun 1;136(11):2717-29.

APE BIO

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE BIO

APE BIO

APE BIO

APE BIO

APE BIO

APE BIO